US CDC recommends expanding pneumococcal vaccines to adults aged 50-64
Updates Oct 23 story to add CDC comment in paragraph 4, Merck statement in paragraph 6
Oct 24 (Reuters) -The U.S. Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between 50-64 years to protect against pneumococcal disease.
The agency's earlier recommendation for vaccination was for adults 65 years or older and children younger than 5, as well as for children and adults with certain conditions.
Children younger than five and adults above 65 are at an increased risk of contracting pneumococcal disease, which can cause infections, including lung pneumonia, and spreads through contact with secretions such as saliva or mucus.
The agency's Advisory Committee on Immunization Practices voted 14 to one in favor of lowering the age for adult vaccination, which the CDC said gives more people the chance to protect against the disease at ages when the risk of infection increases substantially.
Pneumococcal vaccines from Merck MRK.N and Pfizer PFE.N are currently available in the U.S. market.
"The recommendation ... is a significant step forward in efforts to enhance equitable access to pneumococcal conjugate vaccines and may improve vaccination rates," Merck said in a statement.
Merck offers three approved pneumococcal vaccines, including Vaxneuvance for individuals aged six weeks and older and Pneumovax 23 for adults over 50 and children above two.
In June, the U.S. health regulator approved Capvaxive, Merck's next-generation vaccine that helps produce an immune response against 21 serotypes of the bacteria, for adults aged 18 years and above.
Pfizer's Prevnar 20, which protects against 20 serotypes, is approved for individuals above six weeks of age.
Reporting by Sriparna Roy, Sneha S K and Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Savio D'Souza
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
